|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.065 AUD | 0.00% |
|
0.00% | -18.75% |
| Apr. 16 | Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing | MT |
| Mar. 27 | Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II | MT |
Amplia Therapeutics Limited reported earnings results for the half year ended September 30, 2022. For the half year, the company reported revenue was AUD 1.78 million compared to AUD 0.762747 million a year ago. Net loss was AUD 2.91 million compared to AUD 1.32 million a year ago.
Basic loss per share from continuing operations was AUD 0.015 compared to AUD 0.0109 a year ago. Diluted loss per share from continuing operations was AUD 0.015 compared to AUD 0.0109 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -18.75% | 8.22M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
AMPLIA THERAPEUTICS LIMITED 
